Value Pharma Holistic Remedies Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 03-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 03-07-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.36 Cr
as on 03-07-2024
- Revenue -9.33%
(FY 2023)
- Profit -2.57%
(FY 2023)
- Ebitda 12.31%
(FY 2023)
- Net Worth 4.62%
(FY 2023)
- Total Assets -28.28%
(FY 2023)
About Value Pharma Holistic Remedies
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹6.36 Cr.
Janaki Byra, Nehru Mamidi, and Venkata Patanene serve as directors at the Company.
- CIN/LLPIN
U85100TG2010PTC067178
- Company No.
067178
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Value Pharma Holistic Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Janaki Byra  | Director | 27-Aug-2020 | Current |
| Nehru Mamidi | Director | 22-Jan-2024 | Current |
| Venkata Patanene | Director | 22-Jan-2024 | Current |
Financial Performance of Value Pharma Holistic Remedies.
Value Pharma Holistic Remedies Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.33% decrease. The company also saw a slight decrease in profitability, with a 2.57% decrease in profit. The company's net worth moved up by a moderate rise of 4.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Value Pharma Holistic Remedies?
In 2023, Value Pharma Holistic Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Venkart E-Com Private LimitedActive 12 years 9 monthsJanaki Byra and Nehru Mamidi are mutual person
- Sri Dira Constructions And Developers Private LimitedActive 1 year 2 months
Janaki Byra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jan 2011 | ₹6.36 Cr | Open |
How Many Employees Work at Value Pharma Holistic Remedies?
Unlock and access historical data on people associated with Value Pharma Holistic Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Value Pharma Holistic Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Value Pharma Holistic Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
